Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/332648
Title: Development of validated analytical and bioanalytical methods for newer drug formulations
Researcher: Susheel John Varghese
Guide(s): Ravi T K and Francis Saleshier M
Keywords: High-performance liquid chromatography (HPLC)
High-performance thin layer chromatography (HPTLC)
Newer drug formulations
University: The Tamil Nadu Dr. M.G.R. Medical University
Completed Date: 2011
Abstract: Most countries face high and increasing rates of cardiovascular disease (CVDs). Cardiovascular diseases are the number one cause of death globally. The variety and scope of cardiovascular drugs have increased immensely in the past few decades and new drugs are being approved annually. The term cardiovascular drug refers to any medication that affects the heart, blood vessels or the circulatory system. These drugs can be used alone or in combination with each other in the treatment of a variety of disease states such as hypertension, acute coronary syndromes, congestive heart failure (CHF), arrhythmias and dyslipidemias. This thesis deals with the development of precise and accurate validated analytical and bioanalytical methods for the determination of newer cardio vascular drug combinations from formulations and biological fluids. CVDs are caused by disorders of the heart and blood vessels and include coronary heart disease (heart attacks), cerebrovascular disease (stroke), raised blood pressure (hypertension), peripheral artery disease, rheumatic heart disease, congenital heart disease and heart failure. More people die annually from CVDs than from any other cause. An estimated 17.1 million people died from CVDs in 2004, representing 29 % of all global deaths. Among these deaths, an estimated 7.2 million were due to coronary heart disease and 5.7 million were due to stroke. Low- and middle-income countries are disproportionally affected: 82% of CVD deaths take place in low- and middle income countries and occur almost equally in men and women. By 2030, almost 23.6 million people will die from CVDs, mainly from heart disease and stroke. These are projected to remain the single leading cause of death. Higher CVD rates will also have an economic impact. As the number of medications that a patient requires increases, adherence and compliance to therapy are likely to decrease. Hence, to avoid these problems and to give better therapeutic effect, combination therapy has become more popular. newline
Pagination: 386
URI: http://hdl.handle.net/10603/332648
Appears in Departments:Department of Pharmacy

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File37.79 kBAdobe PDFView/Open
02_certificate.pdf28.14 kBAdobe PDFView/Open
03_preliminary pages.pdf138.75 kBAdobe PDFView/Open
04_chapter 1.pdf168.68 kBAdobe PDFView/Open
05_chapter 2.pdf230.51 kBAdobe PDFView/Open
06_chapter 3.pdf85.47 kBAdobe PDFView/Open
07_chapter 4.pdf252.83 kBAdobe PDFView/Open
08_chapter 5.pdf92.65 kBAdobe PDFView/Open
09_chapter 6.pdf69.47 kBAdobe PDFView/Open
10_chapter 7.pdf216.11 kBAdobe PDFView/Open
11_chapter 8.pdf2.25 MBAdobe PDFView/Open
12_references.pdf68.64 kBAdobe PDFView/Open
13_appendix.pdf2.59 MBAdobe PDFView/Open
80_recommendation.pdf134.72 kBAdobe PDFView/Open
Show full item record


Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: